Rhythm Pharmaceuticals, Inc.
bivamelagon
hypothalamic obesity
Countdown
177days
Phase 3 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 3 trial results for bivamelagon in hypothalamic obesity are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“Initiate a pivotal Phase 3 trial evaluating bivamelagon in acquired HO by year-end 2026.”